Natera Partners With Aveta On Late-Stage Head And Neck Cancer Trial
Natera, Inc. (NASDAQ: NTRA ), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Aveta’s global Phase 3 registrational cl